The journnal Cancer Chemotherapy and Pharmacology has recently published the randomized, double-blind, phase III and comparative clinical study of pharmacokinetics and pharmacodynamics between RTXM83 rituximab biosimilar and its reference product in diffuse large B-cell lymphoma patients (Press release, mAbxience, MAR 6, 2018, View Source [SID1234525381])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

.
The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and Cmax). To demonstrate biosimilarity at pharmacokinetic level as required by regulatory agencies, a population pharmacokinetic analysis was performed to compare RTXM83 with respect to the reference product. For this purpose, 5,431 serum samples from 251 recruited patients were used. The systemic exposure of RTXM83 and its associated variability were similar to those for rituximab reference, demonstrating PK similarity. The PD similarity of RTXM83 and rituximab reference product was also demonstrated.

on March 6, 2018 Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, reported that the Company will host a conference call and live webcast on Tuesday, March 13, 2018 at 5:00 p.m. Eastern to report its fourth quarter and full year 2017 financial results and provide a corporate update (Press release, Bellicum Pharmaceuticals, MAR 6, 2018, View Source [SID1234524410]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, participants should dial 877-407-3103 (U.S. domestic) and 201-493-6791 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investors & Media section of the Bellicum website for at least two weeks following the call.

On March 6, 2018 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, reported that it will be presenting at the 30th Annual ROTH Conference, being held on March 11-14, 2018 in Dana Point, California and participate in a NASH panel discussion titled "News is Great, Novel is Better (Press release, Can-Fite BioPharma, MAR 6, 2018, View Source [SID1234524440])".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panel discussions on the latest topics and developments in NASH/PBC drug development span two days at the Roth Conference and are slated to feature 20 public and private companies in the field of liver diseases, 8renowned Key Opinion Leaders, 3 NASH/PBC patients, and The American Liver Foundation.

In addition, Dr. Fishman will deliver the Company’s corporate presentation and provide updates on its lead drug candidate, Piclidenoson (CF101), currently in a Phase III trial for rheumatoid arthritis and is expected to enter a Phase III trial for psoriasis during 2018. The Company’s liver drug Namodenoson (CF102) is in a Phase II trial for patients with advanced liver cancer and is in a Phase II trial for the treatment of NAFLD/NASH.

The company recently provided an update on the progress of its ongoing Phase II NASH study and anticipates the completion of patient enrollment toward the end of 2018 and data release in the first half of 2019.

There is currently no U.S. FDA approved drug for the treatment of NASH, which is an addressable pharmaceutical market estimated to reach $35-40 billion by 2025.

On March 6, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), reported that it will present at the 30th Annual Roth conference taking place on March 11-13 at The Ritz Carlton Hotel in Dana Point, California (Press release, Onconova, MAR 6, 2018, View Source [SID1234524458]). The Company’s Chief Medical Officer, Dr. Steven Fruchtman, will present and be available for one-on-one meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Date: Monday, March 12th, 2018

Time: 7:00 am PT

Location: The Ritz Carlton in Dana Point, Salon 6

The presentation will be available here on the Company’s website.

On March 6, 2018 -Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, reported that Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer, will present a company overview at the Cowen and Company 38th Annual Health Care Conference in Boston, Mass (Press release, Bicycle Therapeutics, JUN 6, 2018, View Source [SID1234524526]). The presentation will take place at 4:30 p.m. on Tuesday, March 13, 2018 at The Boston Marriott Copley Place.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!